Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed, measurable germ cell cancer relapsed or refractory after frontline therapy with cisplatin and etoposide-containing chemotherapy
• Other chemotherapy-sensitive solid tumors eligible (as of 06/11/97)
• Possibility of residual mass representing benign teratoma must be excluded
• Elevated serum tumor markers only are acceptable if possibilities of false-positive serum tumor markers or sanctuary disease have been excluded
• Also eligible after two to four cycles of conventional dose salvage chemotherapy, regardless of response
• No CNS or bone marrow involvement
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 60-100%
• Life expectancy:
• Greater than 2 months
• Hematopoietic:
• Platelet count at least 100,000/mm3
• Neutrophil count at least 1,500/mm3
• Hepatic:
• Bilirubin, alkaline phosphatase, SGOT, and SGPT less than 3 times upper limit of normal, unless due to disease
• Renal:
• Creatinine less than 1.5 times upper limit of normal
• Creatinine clearance at least 60 ml/min
• Cardiovascular:
• Ventricular ejection fraction at least 45%
• No uncontrolled or severe cardiovascular disease including recent myocardial infarction, congestive heart failure, angina, life-threatening arrhythmia, or hypertension
• Pulmonary:
• DLCO and spirometry greater than 50% of predicted
• Other:
• Not HIV positive
• No active peptic ulcer
• No uncontrolled diabetes mellitus
• No active infection
• No previous or concomitant malignancy other than curatively treated basal or squamous cell carcinoma of the skin
• Not HBsAG positive
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• No prior high-dose carboplatin, etoposide, or cyclophosphamide
• Endocrine therapy:
• Not specified
• Radiotherapy:
• Not specified
• Surgery:
• Not specified